AZD0120 clinical trials
AZD0120 is named as an intervention in 18 current clinical trials in our China, USA, UK, Canada, Australia, Germany, Spain, France, Italy, Poland, Brazil, Japan, South Korea, Taiwan, Sweden, Denmark, Norway, Singapore and Egypt registers. 15 are recruiting patients now. The most common phase is Phase 1/2. The sponsor with the most trials is AstraZeneca (7). The most-studied condition is Systemic Sclerosis. The EU clinical trials register (CTIS) separately lists 3 authorised or ongoing trials.
Patient leaflets for AZD0120
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of AZD0120
18 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
AZD0120 in the EU trials register (CTIS)
3 trialsAuthorised or ongoing trials in the EU Clinical Trials Information System that list a product containing AZD0120. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
Conditions studied with AZD0120
23 conditionsAll 23 conditions
| Condition (as registered) | Trials |
|---|---|
| Systemic Sclerosis | 2 |
| Multiple Myeloma | 2 |
| Generalized Myasthenia Gravis (gMG) | 2 |
| Newly Diagnosed Multiple Myeloma | 1 |
| Lupus Erythematosus, Systemic | 1 |
| Relapsed Refractory Multiple Myeloma | 1 |
| Relapsed AL Amyloidosis | 1 |
| Refractory AL Amyloidosis | 1 |
| Light Chain Amyloidosis | 1 |
| Amyloidosis | 1 |
| Newly Diagnosed Multiple Myeloma (NDMM) | 1 |
| Idiopathic Inflammatory Myopathies | 1 |
| Rheumatoid Arthritis | 1 |
| Relapsed/Refractory Multiple Myeloma | 1 |
| Highly Sensitized Patients Awaiting Kidney Transplant | 1 |
| Relapsed/Refractory AL Amyloidosis | 1 |
| Idiopathic Inflammatory Myopathy (IIM) | 1 |
| CAR-T Cell Therapy | 1 |
| Refractory Systemic Lupus Erythematosus | 1 |
| SLE - Systemic Lupus Erythematosus | 1 |
| Refractory Lupus Nephritis | 1 |
| Primary Sjogren's Syndrome Combined With Pulmonary Hypertension | 1 |
| Other Autoimmune Diseases (AID) | 1 |
Sponsors
lead sponsor per trialBy country register
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
Related compounds
Questions about AZD0120 trials
How many clinical trials are testing AZD0120?
18 current trials in our China, USA, UK, Canada, Australia, Germany, Spain, France, Italy, Poland, Brazil, Japan, South Korea, Taiwan, Sweden, Denmark, Norway, Singapore and Egypt registers name AZD0120 (also registered as GC012F) as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are AZD0120 trials recruiting patients?
Yes. 15 of the 18 trials are recruiting: 9 with sites in China, 8 with sites in USA, 6 with sites in UK, 5 with sites in Canada, 5 with sites in Australia, 4 with sites in Germany, 4 with sites in Spain, 3 with sites in France, 3 with sites in Italy, 3 with sites in Poland, 3 with sites in Brazil, 3 with sites in Japan, 3 with sites in South Korea, 3 with sites in Taiwan, 2 with sites in Sweden, 2 with sites in Denmark, 2 with sites in Norway, 1 with sites in Singapore and 1 with sites in Egypt. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors AZD0120 clinical trials?
AstraZeneca (7), Gracell Biotechnologies (Shanghai) Co., Ltd (3), Daishi Tian (2) and Alexion Pharmaceuticals, Inc (1), among 9 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how AZD0120 works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how AZD0120 works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists AZD0120 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.